Medicine or supplement? The classification question that decides your European launch

The same formula can be a medicinal product in one European market and a food supplement in another. That single determination drives your dossier, your packaging, your channel and your entire claim vocabulary — and it cannot be revisited cheaply once artwork is printed.

Why classification comes first

Every downstream cost assumption in a European launch depends on one binary: is this product a medicine or a food supplement? The answer determines whether you need a marketing authorisation or a notification, whether your pack carries an indication or a nutrition claim, whether pharmacies stock it as a therapeutic product or as consumer health, and how much of your marketing budget survives legal review.

Teams routinely defer the question because it feels like a formality that regulatory affairs will sort out later. It is not a formality. It is the single most expensive decision to reverse.

Classification determines the dossier before a single pack is printed.

What actually decides it

Three factors dominate. The pharmacological effect of the substance at the intended dose. The presentation of the product — how it is described, packaged and advertised. And national interpretation, which is why identical products diverge across borders.

A botanical extract dosed below its pharmacologically active threshold and presented without therapeutic indications will normally sit in the food-supplement regime. Raise the dose, or describe a therapeutic effect on the pack, and the product moves into the medicinal-product regime — where an authorisation is required before a single unit may be sold.

Dose is objective. Interpretation is not. EU-level definitions are stable, but the thresholds applied to botanical actives are set nationally and revised over time. A product that cleared assessment in one market three years ago is not automatically safe in a neighbouring market today.

Most reclassification problems we see are not formulation problems. They are copy problems.

Presentation: the common trap

A supplement whose website promises to “treat” a condition has presented itself as a medicine, regardless of its dose. Authorities read the whole commercial context: pack, leaflet, website, retailer listings, influencer content and advertising. A compliant pack paired with non-compliant web copy is still a non-compliant product.

Our own brands are built the same way — medicinal and supplement communication run separately, including within a single brand family such as EMASEX®, where an authorised medicine and a supplement range sit under one name. It is the part partners underestimate most often.

Pack, leaflet and website are assessed together — not separately.

A workable sequence

The order of operations matters more than the speed of any single step:

1. Screen the formula against active thresholds — per ingredient, per target market. Differences between CH, DE and AT are the norm, not the exception.
2. Fix the claim vocabulary in writing — decide which authorised claims you will use, and prohibit everything else across all channels, including retail partners and affiliates.
3. Confirm the regulatory route per market — notification, authorisation or a hybrid path, with realistic timelines attached.
4. Then design the pack. Artwork last. It is the most expensive thing to redo and the easiest thing to get legally wrong.

Country differences within DACH

Switzerland sits outside the EU regulatory framework, with its own authorisation process and its own view on borderline products. Germany and Austria apply EU definitions but differ in enforcement practice and in the tolerance shown to botanical dosages.

In practice this means a DACH launch is three regulatory assessments, not one — and that sequencing markets deliberately, rather than launching everywhere at once, materially reduces risk. We cover that in our market-access service.

Frequently asked

Can the same product be a medicine in one EU country and a supplement in another? Yes. The EU sets the definitions, but national authorities apply them. Dose thresholds for botanical actives and the assessment of presentation differ, so divergent outcomes between Switzerland, Germany and Austria are common rather than exceptional.

Who decides the classification? The competent national authority. A manufacturer can form a well-evidenced view — and should, before investing — but cannot self-certify a binding classification.

How long does a classification assessment take? For a documented formulation with a defined positioning, we typically return an assessment within two weeks, including the regulatory route per target market.

What happens if a supplement is reclassified as a medicine? Distribution must stop until an authorisation exists. Artwork, claims and channel agreements usually have to be rebuilt, which is why the question belongs at the start of a project.

---

If you are unsure which regime your product falls into, that is the assessment we run first in any market-access engagement — usually within two weeks of receiving the formulation and intended positioning.